“Cancer remains an affliction for mankind. After lung cancer, breast cancer happens to be the second most frequent form of cancer. Worldwide, it is the commonest cancer among females. It accounts for 11.6 % of all cancers with 2,088,849 new diagnosed cases and 626,679 yearly deaths in spite of refinements in diagnosis and treatment modalities”.1 “Triple negative breast cancers are an intricate and composite group of cancers and have several molecular subtypes. Tumors that don’t express estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor” 2 (HER2) “are called as triple negative breast cancer (TNBC).2 The consequences in terms of survival and disease-free interval are poor.3,4 They have a distinctive and peculiar pathological and molecular behavior”.